NewsRx

Search our medical news database

Renal Cell Carcinoma

Dendritic Cell Vaccines Evaluated

Published in Cancer Weekly, May 16th, 2000

Researchers from the United States evaluated dendritic-cell-based vaccines for renal cell carcinoma (RCC) using tumor antigens.

"Although RCC has been shown to respond to immunotherapy, RCC-specific rejection antigens and their corresponding cytotoxic T lymphocyte (CTL) epitopes have rarely been described," noted Johannes Vieweg and colleagues from Duke University Medical Center, North Carolina. "The use of dendritic cells (DC) transfected with antigen encoded in tumor RNA may allow specific immunotherapy even in cancers in which relevant rejection antigens have, so far, not been identified."

Vieweg et al. presented data from their study at the...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook